Posted by Michael Wonder on 25 Sep 2019
NICE terminates another three assessments
25 September 2019 - NICE has terminated 11 assessments so far this year.
NICE has announced that it has terminated the following assessments:
- Bezlotoxumab for preventing recurrent Clostridium difficile infection (TA601)
- Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (TA602)
- Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (TA603)
